INT258404

From wiki-pain
Revision as of 21:49, 22 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.28
First Reported 2007
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 6
Disease Relevance 1.08
Pain Relevance 2.24

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (ACR) DNA binding (ACR) protein complex (ACR)
ACR (Homo sapiens)
Pain Link Frequency Relevance Heat
methotrexate 123 99.64 Very High Very High Very High
abatacept 359 95.32 Very High Very High Very High
Adalimumab 6 90.36 High High
Etanercept 18 86.32 High High
corticosteroid 40 85.68 High High
Infliximab 18 85.12 High High
rheumatoid arthritis 252 67.60 Quite High
anakinra 3 66.76 Quite High
Inflammation 53 5.00 Very Low Very Low Very Low
cytokine 31 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disease 146 99.36 Very High Very High Very High
Pneumocystis Pneumonia 1 82.64 Quite High
Hyperlipidemia 5 81.68 Quite High
Rheumatoid Arthritis 260 67.60 Quite High
Nephrotoxicity 13 58.24 Quite High
Injury 2 21.40 Low Low
Thrombosis 4 21.04 Low Low
INFLAMMATION 68 5.00 Very Low Very Low Very Low
Infection 64 5.00 Very Low Very Low Very Low
Hepatitis C Virus Infection 52 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Additionally, those patients receiving 4 mg/kg or 8 mg/kg of tocilizumab in combination with MTX also achieved an ACR50 and ACR70 response that was significantly increased in comparison with MTX alone.
Positive_regulation (increased) of Gene_expression (response) of ACR70 associated with methotrexate
1) Confidence 0.28 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.07 Pain Relevance 0.36
Additionally, those patients receiving 4 mg/kg or 8 mg/kg of tocilizumab in combination with MTX also achieved an ACR50 and ACR70 response that was significantly increased in comparison with MTX alone.
Positive_regulation (increased) of Gene_expression (response) of ACR50 associated with methotrexate
2) Confidence 0.28 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.07 Pain Relevance 0.36
Significant differences were also observed for ACR50 and ACR70 responses as well as low disease activity or remission according to the DAS-28 (Fig. 1).
Positive_regulation (observed) of Gene_expression (responses) of ACR70 associated with disease
3) Confidence 0.06 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012435 Disease Relevance 0.32 Pain Relevance 0.50
Significant differences were also observed for ACR50 and ACR70 responses as well as low disease activity or remission according to the DAS-28 (Fig. 1).
Positive_regulation (observed) of Gene_expression (responses) of ACR50 associated with disease
4) Confidence 0.06 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012435 Disease Relevance 0.32 Pain Relevance 0.50
Primary endpoints were percentage of patients achieving an ACR20 response and a significant improvement (?
Positive_regulation (improvement) of Gene_expression (response) of ACR20
5) Confidence 0.05 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012435 Disease Relevance 0.09 Pain Relevance 0.47
Only one patient (3%) experienced ACR who upon further investigation was discovered to have discontinued sirolimus.
Positive_regulation (experienced) of Gene_expression (experienced) of ACR
6) Confidence 0.03 Published 2009 Journal Journal of Transplantation Section Body Doc Link PMC2809333 Disease Relevance 0.22 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox